BioNTech is tearing up its old playbook. The Mainz-based biotech, which shot to global fame on the back of the first approved mRNA vaccine, is now executing a radical pivot to oncology that will see both of its founders walk away and the company shed nearly 2,000 jobs. Yet the stock, battered but resilient, is already pricing in a turnaround: shares closed Friday at €84.30, up almost 10% over the past month and roughly 23% above the 52-week low of €68.35 hit on 10 March.
The transformation goes beyond the balance sheet. CEO and co-founder Ugur Sahin, together with his wife and chief medical officer Özlem Türeci, will leave the company at the end of 2026. Their departure is the clearest signal yet that BioNTech is no longer the start-up it once was, but a full-fledged oncology group betting its future on a pipeline of cancer therapies.
Moderna circlesRead More
as BioNTech unloads German plants
In the most tangible restructuring move, BioNTech is in confidential talks to sell its production sites in Idar-Oberstein, Marburg and Tübingen, all slated for closure by the end of 2027. US vaccine rival Moderna has emerged as a potential buyer. Moderna chief Stéphane Bancel has publicly flagged that acquiring existing facilities could speed up operational readiness far more than building from scratch — provided a suitable agreement can be reached with the German government.
The factory sell-off will cost roughly 1,860 jobs. The Berlin-based subsidiary JPT Peptide, which BioNTech acquired in 2009 but now runs at a loss, is also being closed by year-end, forcing the company to find a new peptide supplier. The retreat from Singapore adds further headcount reductions. Major shareholder Bernd Förtsch is already exploring legal action against the direction the management is taking.
Should investors sell immediately? Or is it worth buying BioNTech?
Cash cushion funds a pipeline gamble
Despite the upheaval, BioNTech is sitting on a hefty war chest. Liquid assets and marketable securities total €16.8 billion, providing a long runway for its oncology push even as revenue craters. First-quarter 2026 revenue dropped to €118.1 million from €182.8 million a year earlier, while the net loss widened to €531.9 million. For the full year, management expects sales of no more than €2.3 billion — a far cry from the nearly €19 billion the company booked at the height of the pandemic.
That cash is being poured into cancer research at an accelerating pace. BioNTech aims to have 15 phase‑3 studies running simultaneously by the end of 2026, with several late-stage data readouts across different tumour types scheduled for this year. A cornerstone of the new strategy is the ADC (antibody-drug conjugate) pipeline. A settlement with partner Yilian Biologics has secured the licence for the candidate YL202, while fellow developer Duality Biologics is pushing ahead with an initial public offering in Shanghai. BioNTech shares key oncology patents with the Chinese firm.
Stock buyback and technicals
Since 8 June 2026, BioNTech has been running a share buyback programme of up to US$1 billion, which will continue until 6 May 2027. The programme underlines management’s belief that the equity is undervalued given the pipeline potential. Technical traders note that the stock currently sits above its 50‑day moving average of around €80, but just below the 200‑day average of €85.35. The 30‑day annualised volatility stands at roughly 31%, reflecting the uncertainty surrounding the corporate overhaul.
For BioNTech, a successful sale of the German plants would achieve two things at once: remove the cost burden of idled factories and free up capital to fund the oncology pipeline on which the entire future now depends. The founders’ exit in 2026 adds a hard deadline to that transformation.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from July 6 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 6.
BioNTech: Buy or sell? Read more here...
